Sleep Dysregulation Is Associated with 18 F-FDG PET and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease.

Mariana FernandesAgostino ChiaravallotiMarzia NuccetelliFabio PlacidiFrancesca IzziRiccardo CameddaSergio BernardiniGiuseppe SancesarioOrazio SchillaciNicola Biagio MercuriClaudio Liguori

Published in: Journal of Alzheimer's disease reports (2023)

Sleep impairment, namely sleep fragmentation, REM sleep dysregulation, and difficulty in initiating sleep correlates with AD biomarkers, suggesting an effect of sleep on the pathological processes in different AD stages. Targeting sleep for counteracting the AD pathological processes represents a timely need for clinicians and researchers.

Keyphrases

sleep quality
physical activity
cognitive decline
drug delivery
cancer therapy
mild cognitive impairment